Article Text

Download PDFPDF
Monitoring of Endometrial K-ras Mutation in Tamoxifen-Treated Patients With Breast Cancer
  1. Hiroshi Tsujioka, MD*,
  2. Toru Hachisuga, MD,
  3. Miyoko Fukuoka, MD*,
  4. Taeko Ueda, MD*,
  5. Daisuke Miyahara, MD*,
  6. Shinji Horiuchi, MD*,
  7. Kyoko Shirota, MD*,
  8. Toshiyuki Yoshizato, MD*,
  9. Makoto Emoto, MD*,
  10. Shingo Miyamoto, MD* and
  11. Tatsuhiko Kawarabayashi, MD*
  1. * Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka; and
  2. Department of Obstetrics and Gynecology, University of Occupational and Environmental Health, Kitakyushu, Japan.
  1. Address correspondence and reprint requests to Hiroshi Tsujioka, MD, Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan. E-mail: tsujioka{at}


Introduction: A high incidence of endometrial K-ras mutations has been reported in tamoxifen (TAM)-treated patients with breast cancer. We examined the changes in the frequency of the endometrial K-ras mutations after the cessation of TAM treatment.

Methods: DNA was extracted from fresh cytological or polypectomy samples of the endometrium in 28 patients who had undergone TAM treatment of breast cancer. Mutations were detected by an enriched polymerase chain reaction-enzyme-linked minisequence assay (Sumitomo Metal Industry, Inc, Tokyo, Japan). K-ras codon 12 mutations were monitored in these 28 patients.

Results: An initial examination detected endometrial K-ras mutations in 13 of the 28 patients. However, repeated examinations performed after cessation of TAM treatment did not detect endometrial K-ras mutations in any of these 13 patients. No endometrial K-ras mutation has been detected in the repeated examinations performed for these patients for more than 2 years since the cessation of TAM treatment. In addition, the 15 patients who did not have endometrial K-ras mutations in the initial examination did not demonstrate them in repeat examinations.

Conclusions: The cessation of TAM treatment may reduce the risk of developing endometrial cancers through K-ras mutations.

  • Tamoxifen
  • K-ras
  • Endometrium
  • Breast cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.